spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

York Health Economics Consortium offers a new health utilities training course

YHEC


Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.

Our new one-day Health Utilities for Economic Models course, running on 4th July 2018, complements our Early Economic Modelling course. It outlines different approaches to obtaining utility values and provides an overview of the associated strengths and limitations across different contexts. Examples of the different approaches used in real-world NICE health technology assessments will be shared, with comments from evidence review groups, and we will take a look at the limitations of utilities and discuss how alternative approaches might be used in the future.

For those also interested in patient reported outcome measures more generally, York Health Economics Consortium is also running the Introduction to Patient Reported Outcomes Measures training course on the 7th March this year.
phone +44 (0)1904 323620
email andria.hanbury@york.ac.uk
web www.yhec.co.uk/
email Address: YHEC, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement